Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
Tiziana Life Sciences said Thursday it has developed investigational new technology to treat COVID-19 infections.
Novartis said on Thursday it aims to start a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, reports that many of its member companies are actively involved in helping their clients develop and produce treatments, vaccines, and diagnostics for COVID-19. PBOA’s members provide a wide array of services throughout the bio/pharma sector.
PCR Biosystems, the UK-based PCR experts, PCR Biosystems has the capacity to manufacture enough reagent daily for 4 million reactions – which is sufficient for millions of diagnostic tests
Apeiron Biologics AG has received regulatory approvals in Austria, Germany and Denmark to kickoff a Phase II clinical trial of APN01 to treat COVID-19.
Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local…
German biopharmaceutical company InflaRx has enrolled the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, the company´s monoclonal anti-C5a antibody, in patients with severe COVID-19-induced pneumonia.
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates…
N4 Pharma will test a Covid-19 DNA plasmid if Nuvec, a novel delivery system for cancer treatments and vaccines, can be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.